Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis.
Extracorporeal membrane oxygenation (ECMO)
lung transplantation (LTx)
primary graft dysfunction
Journal
Annals of cardiothoracic surgery
ISSN: 2225-319X
Titre abrégé: Ann Cardiothorac Surg
Pays: China
ID NLM: 101605877
Informations de publication
Date de publication:
Jan 2019
Jan 2019
Historique:
entrez:
12
3
2019
pubmed:
12
3
2019
medline:
12
3
2019
Statut:
ppublish
Résumé
Lung transplantation is the treatment of choice for end-stage pulmonary disease in selected patients. However, severe primary graft dysfunction is a significant complication of transplant and requires the implantation of an extracorporeal support. The aim of the study is to evaluate the impact of extracorporeal membrane oxygenation (ECMO) after transplant in our center. From January 2008 till June 2018, 195 consecutive unselected patients receiving a lung transplant were considered. Mean age was 49±15 years. Main indications for transplant were idiopathic pulmonary fibrosis in 72 patients, chronic obstructive pulmonary disease in 60 patients, and cystic fibrosis in 40 patients. Prior to transplant, 18 patients were on mechanical ventilation and 14 were on ECMO. Twenty-five patients required venous-venous ECMO after transplant. Vascular disease as cause of transplant [relative risk (RR) 7.8, 95% CI: 1.5-41, P=0.02], donor age (RR 1.6, 95% CI: 1.03-2.3, P=0.03) and need for cardiopulmonary by-pass during transplant (RR 3.1, 95% CI: 1.02-9, P=0.04) were associated with ECMO implantation. Patients requiring post-transplant ECMO received more transfusions (P<0.01), had a longer mechanical ventilation (P<0.01) and ICU stay (P<0.01) and had a higher hospital mortality (P<0.01). Post-transplant ECMO significantly influenced one- and five-year survival [hazard ratio (HR) 5.5, 95% CI: 3-10, P<0.001 and HR 3.5, 95% CI: 2-6, P<0.001, respectively]. However, conditional survival after t months is similar for patients with or without post-transplant ECMO. In our experience, although ECMO is a reliable and effective strategy to support pulmonary function, severe graft dysfunction after lung transplantation still has a significant impact on early and late results.
Sections du résumé
BACKGROUND
BACKGROUND
Lung transplantation is the treatment of choice for end-stage pulmonary disease in selected patients. However, severe primary graft dysfunction is a significant complication of transplant and requires the implantation of an extracorporeal support. The aim of the study is to evaluate the impact of extracorporeal membrane oxygenation (ECMO) after transplant in our center.
METHODS
METHODS
From January 2008 till June 2018, 195 consecutive unselected patients receiving a lung transplant were considered. Mean age was 49±15 years. Main indications for transplant were idiopathic pulmonary fibrosis in 72 patients, chronic obstructive pulmonary disease in 60 patients, and cystic fibrosis in 40 patients. Prior to transplant, 18 patients were on mechanical ventilation and 14 were on ECMO.
RESULTS
RESULTS
Twenty-five patients required venous-venous ECMO after transplant. Vascular disease as cause of transplant [relative risk (RR) 7.8, 95% CI: 1.5-41, P=0.02], donor age (RR 1.6, 95% CI: 1.03-2.3, P=0.03) and need for cardiopulmonary by-pass during transplant (RR 3.1, 95% CI: 1.02-9, P=0.04) were associated with ECMO implantation. Patients requiring post-transplant ECMO received more transfusions (P<0.01), had a longer mechanical ventilation (P<0.01) and ICU stay (P<0.01) and had a higher hospital mortality (P<0.01). Post-transplant ECMO significantly influenced one- and five-year survival [hazard ratio (HR) 5.5, 95% CI: 3-10, P<0.001 and HR 3.5, 95% CI: 2-6, P<0.001, respectively]. However, conditional survival after t months is similar for patients with or without post-transplant ECMO.
CONCLUSIONS
CONCLUSIONS
In our experience, although ECMO is a reliable and effective strategy to support pulmonary function, severe graft dysfunction after lung transplantation still has a significant impact on early and late results.
Identifiants
pubmed: 30854312
doi: 10.21037/acs.2018.12.10
pii: acs-08-01-54
pmc: PMC6379200
doi:
Types de publication
Journal Article
Langues
eng
Pagination
54-61Déclaration de conflit d'intérêts
Conflicts of Interest: The authors have no conflicts of interest to declare.
Références
Curr Opin Crit Care. 2010 Feb;16(1):53-61
pubmed: 20019609
Minerva Anestesiol. 2012 Feb;78(2):243-50
pubmed: 22293922
Transplant Proc. 2013 Sep;45(7):2624-6
pubmed: 24034008
Eur J Cardiothorac Surg. 2014 Nov;46(5):789-93
pubmed: 25061216
Transplantation. 2015 Feb;99(2):451-8
pubmed: 25119128
Interact Cardiovasc Thorac Surg. 2014 Nov;19(5):795-800; discussion 800
pubmed: 25139285
Transplantation. 2016 May;100(5):1128-35
pubmed: 26425874
J Heart Lung Transplant. 2015 Oct;34(10):1278-82
pubmed: 26454741
J Heart Lung Transplant. 2017 Oct;36(10):1047-1059
pubmed: 28784324
J Heart Lung Transplant. 2017 Oct;36(10):1121-1136
pubmed: 28784325
Eur J Cardiothorac Surg. 2018 Jan 1;53(1):178-185
pubmed: 28950326
J Thorac Cardiovasc Surg. 2018 May;155(5):2193-2206.e3
pubmed: 29653665
Ann Thorac Surg. 1998 Jan;65(1):187-92
pubmed: 9456115